Cargando…
Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, an...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373939/ https://www.ncbi.nlm.nih.gov/pubmed/32369265 http://dx.doi.org/10.1002/ehf2.12716 |